Valuation: Dimerix Limited

Market Cap 123M 86.07M 75.6M 70.3M 64.51M 121M 8.29B 835M 326M 4.08B 323M 316M 14.09B P/E 2024
-13.5x
P/E 2025 -24.3x
Enterprise Value 54.9M 38.39M 33.72M 31.36M 28.77M 54.06M 3.7B 372M 145M 1.82B 144M 141M 6.28B EV / Sales 2024
443x
EV / Sales 2025 49.4x
Free-Float
77.77%
Yield 2024 *
-
Yield 2025 -
1 day+4.17%
1 week+4.17%
Current month+21.95%
1 month+25.00%
3 months-34.21%
6 months-51.92%
Current year-54.55%
1 week 0.22
Extreme 0.22
0.26
1 month 0.2
Extreme 0.195
0.27
Current year 0.16
Extreme 0.157
0.56
1 year 0.16
Extreme 0.157
0.66
3 years 0.06
Extreme 0.061
0.78
5 years 0.05
Extreme 0.052
0.78
10 years 0.05
Extreme 0.052
0.78
Manager TitleAgeSince
Chief Executive Officer - 26/08/2018
Director of Finance/CFO 59 28/01/2026
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 61 02/07/2015
Chairman - -
Director/Board Member - 26/08/2018
Date Insider Type Main position Quantity % Market Cap.
12/12/25 Free

Chairman

100,000 0.0167%
12/12/25 Free

Chief Executive Officer

333,333 0.0555%
12/12/25 Free

Chairman

100,000 0.0167%
Change 5-day change 1-year change 3-year change Capi.($)
+4.17%+4.17%-55.75%+252.11% 105M
+1.07%-3.49%-3.35%+10.44% 46.86B
+0.25%+1.65%+399.22%+634.87% 40.23B
-0.27%+4.45%+11.81%+65.64% 36.23B
+0.35%+0.87%+4.46%-10.16% 34.72B
+3.14%+1.02%+4.76%+40.92% 27.89B
-0.73%+11.84%+34.39%+134.36% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%-3.43%+9.03% 13.12B
-2.68%-2.49%-11.36%-33.61% 12.7B
Average +0.62%+1.16%+42.31%+122.63% 24.54B
Weighted average by Cap. +0.48%+0.91%+74.36%+136.33%

Financials

2024 2025
Net sales 583K 408K 358K 333K 306K 575K 39.29M 3.96M 1.55M 19.32M 1.53M 1.5M 66.79M 5.59M 3.91M 3.43M 3.19M 2.93M 5.5M 376M 37.89M 14.8M 185M 14.67M 14.35M 640M
Net income -17.08M -11.94M -10.49M -9.75M -8.95M -16.82M -1.15B -116M -45.25M -565M -44.83M -43.86M -1.95B -13.25M -9.27M -8.14M -7.57M -6.95M -13.05M -892M -89.88M -35.12M -439M -34.79M -34.04M -1.52B
Net Debt -21.99M -15.38M -13.51M -12.56M -11.53M -21.66M -1.48B -149M -58.28M -728M -57.73M -56.49M -2.52B -68.19M -47.68M -41.88M -38.95M -35.74M -67.15M -4.59B -462M -181M -2.26B -179M -175M -7.81B
Logo Dimerix Limited
Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company focused on developing new therapies for kidney diseases. The Company's lead program, DMX-200, is in Phase III clinical development for focal segmental glomerulosclerosis (FSGS), a serious and life-threatening rare kidney disease with limited treatment options. In addition, it is advancing a Phase II program in acute kidney injury (AKI), further strengthening its pipeline in high-need renal indications. DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. The Company's DMX-652 is a selective inhibitor of USP30 - a mitochondrial enzyme that slows the removal of damaged mitochondria. The Phase II trial is designed to investigate DMX-652's potential to prevent kidney injury and preserve renal function. It is also developing DMX-700 for respiratory disease.
Employees
15
Date Price Change Volume
24/07/26 A$0.2500 +4.17% 1,091,226
23/07/26 A$0.2400 -4.00% 2,448,999
22/07/26 A$0.2500 +8.70% 1,986,809
21/07/26 A$0.2300 +2.22% 688,279
20/07/26 A$0.2250 -6.25% 2,190,009